Shire Articles
Stock Commentary - European
17 January 2005
Shire and New River deal for ADHD drug
10 January 2005
Lilly adds liver warning to Strattera label
10 January 2005
GTx gets exclusive US rights for Orion's toremifene
20 December 2004
Shire's Equetro cleared by FDA for BD
20 December 2004
Long-term use of Reminyl beneficial
15 November 2004
Stock Commentary - Europe
15 November 2004
Stock Commentary - Europe
8 November 2004
Shire granted extension for Adderall XR by FDA
8 November 2004
US FDA approves Shire's Fosrenol
1 November 2004
Stock Commentary - Europe
25 October 2004
Shire completes sales of vaccines business to ID Biomedical
20 September 2004
Shire Pharma appoints exec VP, business development in USA
13 September 2004
Studies reveal risk of birth defects from AEDs
13 September 2004
Stock Commentary - Europe
6 September 2004
ID Bio provides 2004 guidance
30 August 2004
Stock Commentary - Europe
23 August 2004
FDA OKs Adderall XR for ADHD in adults
23 August 2004
Stock Commentary - Europe
9 August 2004
SGX acquires Shire's anticancer drug
9 August 2004
Shire raises forecasts on good 2nd-qtr
9 August 2004
UPDATE: Shire's Fosrenol faces delay for US approval
26 July 2004
Shire's Fosrenol faces delay for US approval
26 July 2004
Who suffers least if US Rx price pressure grows?
12 July 2004
Eisai/Pfizer's Alzheimer's disease drug Aricept is not cost-effective, says Lancet study
5 July 2004
Noven and Shire in ADHD patch deal
21 June 2004
Shire's Agrylin gets extra market exclusivity
7 June 2004
IMPAX gains FDA clearance for generic Proamatine
7 June 2004
Shire BioChem to sell ImmunoGen stock
24 May 2004
Shire BioChem to sell ImmunoGen stock
24 May 2004
Shire acquires full UK and Ireland rights to Reminyl
12 April 2004
QRxPharma and Shire in Q8003 development deal
29 March 2004
Shire's Fosrenol gets first approval, in Sweden
29 March 2004
Shire pays $31M for Fosrenol patent rights
29 March 2004
Maxim reacquires cancer drug candidates from Shire
22 March 2004
Stock Commentary - Europe
22 March 2004
Strong performace for Shire in 2003
22 March 2004
Stock Commentary - Europe
9 February 2004
Shire's Adderall XR available in Canada
9 February 2004
Stock Commentary - Europe
2 February 2004
Shire Pharma names Anita Graham exec VP, human resources
2 February 2004
Ex-Shire CEO arises with Chesyl Pharma
26 January 2004
Company news briefs
26 January 2004
Stock Commentary - Europe
5 January 2004
Shire files suit against IMPAX
5 January 2004
Kirin licenses Shire's Agrylin in Japan
5 January 2004
Bayer licenses Shire's Fosrenol in Japan
15 December 2003
Shire's Adderall XR facing further generic comp
24 November 2003
Positive new findings for Shire's Fosrenol
24 November 2003
Shire beats expectations in third quarter as ADHD product sales soar
17 November 2003
Stock Commentary - Europe
10 November 2003
Adderall XR on track for US use in adults
27 October 2003
Eli Lilly's Strattera gains 16.3% of new Rxs in the USA
27 October 2003
Amersham confirms bid approach; shares leap to 18-month high
13 October 2003
Promising new data on Shire/J&J's Reminyl
22 September 2003
Mylan gets FDA appro for generic midodrine
22 September 2003
Eon to commence shipping of Shire generic
22 September 2003
Shire files key law suit against Barr Labs
8 September 2003
Stock Commentary - Europe
11 August 2003
Shire unit negotiates Canadian flu vacc deal
4 August 2003
Draxis completes pharma unit divestiture
28 July 2003
Stock Commentary - Europe
28 July 2003
Stock Commentary - Europe
21 July 2003
Shire's Fosrenol cuts phosphate in a week
7 July 2003
Fosrenol shows long term benefit in ESRD
23 June 2003
Stock Commentary - Europe
12 May 2003
Adderall drives growth at Shire in 1st quarter
12 May 2003
Stock Commentary - Europe
5 May 2003
Noven gains $25M from Shire
14 April 2003
Barr's generic Adderall cleared in USA
31 March 2003
Stock Commentary - Europe
24 March 2003
Former Merck man is new CEO at Shire
17 March 2003
Stock Commentary - Europe
10 March 2003
Shire's Fosrenol is approvable, says FDA
10 March 2003
Shire's profits up on switching strategy
3 March 2003
Shire gets tough in Adderall XR defense
3 March 2003
Jean-Francois Bedard named as director of Shire Acquisitions
10 February 2003
SkyePharma licenses more Solaraze rights to Shire
20 January 2003
Shire hit by Adderall XR patent challenge
13 January 2003
Shire sells OTC portfolio for $72M
6 January 2003
Shire
12 August 2002
Altair unveils Renagel, Fosrenol rival
22 July 2002
Celltech considering Metadate sale?
22 July 2002
Ranbaxy gets OK for generic Adderall
1 July 2002
Genzyme General revises 2002 financial guidance
24 June 2002
Novartis' Ritalin LA cleared in USA
17 June 2002
Novartis' Ritalin LA cleared in USA
17 June 2002
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
